Drug Trial Radar · NCT06106581
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
304
Actual
Start
Dec 18, 2023
Primary completion
Jul 31, 2024
Study completion Jul 2, 2025
Sponsor
- Lead sponsor
- Valneva Austria GmbHIndustry
- Sponsor type
- Industry
- First posted
- Oct 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 11 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control. At least 300 male and female healthy children aged 1 to 11 years will be enrolled and the overall distribution of participants will be 2:2:1 to the two VLA1553 dose groups (n=120 each) or control (n=60).
Conditions
- Chikungunya Virus Infection
Interventions
VLA1553 full doseBiological
Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate
VLA1553 half doseBiological
Single intramuscular vaccination on Day 1 with VLA1553 half dose, a lyophilized live-attenuated Chikungunya vaccine candidate
ControlBiological
Nimenrix
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Solicited Injection Site ReactionsTime frame: within 14 days post-vaccination
- Severity of Solicited Injection Site ReactionsTime frame: within 14 days post-vaccination
- Number of Participants With Solicited Systemic ReactionsTime frame: within 14 days post-vaccination
- Severity of Solicited Systemic ReactionsTime frame: within 14 days post-vaccination
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Instituto Dermatologico y Cirugia de la Piel "Dr Huberto Bogaert Diaz" IDCP
Santo Domingo, Dominican Republic
Fundacion Dominicana de Perinatologia Fundacion Probebe
Santo Domingo, Gazcue, Dominican Republic
Inversiones en Investigacion Medica INVERIME
Tegucigalpa, Honduras
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.